Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Blood Transfusion and Agglutination

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...

Mutations

Mutations

Mutations

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...

Mutations

Mutations

Intracellular Signaling Affects Focal Adhesions

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Loss of the oncogenic phosphatase PRL-3 promotes a TNF-R1 feedback loop that mediates triple-negative breast cancer growth.

Oncogenesis·2016

Same author

Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency.

Haemophilia : the official journal of the World Federation of Hemophilia·2016

Same author

Pharmacokinetics of a high-purity plasma-derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiency.

Haemophilia : the official journal of the World Federation of Hemophilia·2016

Same author

Ongoing risk of thrombosis with factor XI concentrate: 5 years experience in two centres.

Haemophilia : the official journal of the World Federation of Hemophilia·2015

Same author

ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective.

Haemophilia : the official journal of the World Federation of Hemophilia·2014

Same author

A novel mutation in the P2Y12 receptor and a function-reducing polymorphism in protease-activated receptor 1 in a patient with chronic bleeding.

Journal of thrombosis and haemostasis : JTH·2014

Search research articles

Related Experiment Video

Updated: Jun 28, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

The JAK2 V617F mutation and thrombosis.

S K Austin¹, J R Lambert

¹Department of Haematology, University College London, London, UK. steve.austin@stgeorges.nhs.uk

British Journal of Haematology

|November 13, 2008

Summary

This summary is machine-generated.

The JAK2 V617F mutation

More Related Videos

Venous Thrombosis Assay in a Mouse Model of Cancer

Venous Thrombosis Assay in a Mouse Model of Cancer

Published on: January 5, 2024

Related Experiment Videos

Last Updated: Jun 28, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Venous Thrombosis Assay in a Mouse Model of Cancer

Venous Thrombosis Assay in a Mouse Model of Cancer

Published on: January 5, 2024

Area of Science:

Hematology
Molecular Biology
Oncology

Background:

Myeloproliferative disorders (MPD) management depends on thrombotic risk.
The JAK2 V617F mutation's role in MPD is under investigation.
Clinical evidence suggests a variable association between JAK2 V617F and thrombosis.

Purpose of the Study:

To investigate the clinical and pathological consequences of the JAK2 V617F mutation in MPD.
To determine if the JAK2 V617F mutation characterizes a distinct MPD subgroup.
To clarify the impact of the JAK2 V617F mutation on thrombotic risk in MPD patients.

Main Methods:

Review of clinical and pathological data of MPD patients.
Analysis of laboratory parameters related to leucocyte and platelet activation.
Assessment of thrombotic risk in relation to JAK2 V617F mutation status.

Main Results:

Increasing clinical evidence suggests the JAK2 V617F mutation is variably associated with thrombosis.
Laboratory findings indicate potential increased activation of leucocytes and platelets in MPD with JAK2 V617F.
The mutation's presence may characterize a distinct subgroup of MPD.

Conclusions:

The JAK2 V617F mutation may be associated with altered thrombotic risk in MPD.
Screening for JAK2 V617F is potentially justified in idiopathic splanchnic vein thrombosis without overt MPD.
Further research is needed to fully elucidate the mutation's role in MPD pathogenesis and clinical outcomes.